# TAC-003

Source: https://onco.cc/drugs/tac-003/  
OnCo record `tac-003` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TAC-003 is an experimental toll-like receptor agonist antibody conjugate from Tallac Therapeutics, in preclinical development for cancer; its current status is not stated.

## Summary

TAC-003 (Nectin-4 TRAAC) is a toll-like receptor agonist antibody conjugate (TRAAC) from Tallac Therapeutics. A TRAAC directed at Nectin-4; the source names only the target. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Preclinical data featured at SITC 2023; no later update found on the company site. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Also known as: Nectin-4 TRAAC
- Tags: pipeline
- Code: TAC-003
- Modality: Toll-like receptor agonist antibody conjugate (TRAAC)
- Mechanism: A TRAAC directed at Nectin-4; the source names only the target.

## Sources

- Tallac Therapeutics: tallactherapeutics.com: https://www.tallactherapeutics.com/news/tallac-presents-first-clinical-data-for-tac-001-at-sitc-2023/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/)
- companies: [Tallac Therapeutics](https://onco.cc/companies/tallac-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/tac-003.json